Nia Impact Advisors LLC lifted its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 12.1% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 10,184 shares of the medical research company's stock after buying an additional 1,100 shares during the quarter. Thermo Fisher Scientific makes up 1.7% of Nia Impact Advisors LLC's portfolio, making the stock its 20th biggest position. Nia Impact Advisors LLC's holdings in Thermo Fisher Scientific were worth $5,298,000 as of its most recent SEC filing.
A number of other large investors also recently modified their holdings of the business. Aprio Wealth Management LLC increased its holdings in shares of Thermo Fisher Scientific by 17.9% in the 4th quarter. Aprio Wealth Management LLC now owns 1,022 shares of the medical research company's stock worth $532,000 after acquiring an additional 155 shares during the period. Fiduciary Alliance LLC acquired a new stake in shares of Thermo Fisher Scientific in the 4th quarter worth about $811,000. Capital Investment Advisors LLC increased its holdings in shares of Thermo Fisher Scientific by 15.4% in the 4th quarter. Capital Investment Advisors LLC now owns 1,335 shares of the medical research company's stock worth $695,000 after acquiring an additional 178 shares during the period. Signet Financial Management LLC acquired a new stake in shares of Thermo Fisher Scientific in the 4th quarter worth about $218,000. Finally, Benson Investment Management Company Inc. increased its holdings in shares of Thermo Fisher Scientific by 0.7% in the 4th quarter. Benson Investment Management Company Inc. now owns 8,149 shares of the medical research company's stock worth $4,239,000 after acquiring an additional 53 shares during the period. 89.23% of the stock is currently owned by institutional investors.
Thermo Fisher Scientific Price Performance
Shares of NYSE:TMO traded up $7.22 during trading hours on Friday, hitting $412.15. 2,498,185 shares of the company's stock traded hands, compared to its average volume of 1,839,114. Thermo Fisher Scientific Inc. has a 52 week low of $390.50 and a 52 week high of $627.88. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.29 and a current ratio of 1.66. The company's fifty day simple moving average is $453.88 and its two-hundred day simple moving average is $510.42. The company has a market cap of $155.58 billion, a price-to-earnings ratio of 24.93, a price-to-earnings-growth ratio of 2.99 and a beta of 0.82.
Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share for the quarter, beating the consensus estimate of $5.10 by $0.05. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. The company had revenue of $10.36 billion during the quarter, compared to analyst estimates of $10.23 billion. During the same quarter last year, the firm posted $5.11 EPS. The business's revenue for the quarter was up .2% on a year-over-year basis. As a group, equities analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.
Thermo Fisher Scientific Increases Dividend
The company also recently announced a quarterly dividend, which was paid on Tuesday, April 15th. Shareholders of record on Friday, March 14th were issued a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 0.42%. This is a boost from Thermo Fisher Scientific's previous quarterly dividend of $0.39. The ex-dividend date was Friday, March 14th. Thermo Fisher Scientific's dividend payout ratio (DPR) is presently 10.09%.
Wall Street Analyst Weigh In
A number of analysts recently weighed in on TMO shares. Citigroup dropped their price objective on shares of Thermo Fisher Scientific from $650.00 to $570.00 and set a "neutral" rating on the stock in a report on Tuesday, March 4th. Stifel Nicolaus lowered their target price on shares of Thermo Fisher Scientific from $665.00 to $620.00 and set a "buy" rating on the stock in a research note on Thursday, April 24th. UBS Group lowered their target price on shares of Thermo Fisher Scientific from $715.00 to $500.00 and set a "buy" rating on the stock in a research note on Thursday, April 24th. Robert W. Baird lowered their target price on shares of Thermo Fisher Scientific from $603.00 to $573.00 and set an "outperform" rating on the stock in a research note on Thursday, April 24th. Finally, Wells Fargo & Company lowered their target price on shares of Thermo Fisher Scientific from $580.00 to $570.00 and set an "overweight" rating on the stock in a research note on Thursday, April 24th. Five analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. According to data from MarketBeat.com, Thermo Fisher Scientific presently has an average rating of "Moderate Buy" and a consensus price target of $607.43.
Check Out Our Latest Analysis on TMO
Insiders Place Their Bets
In other news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction that occurred on Tuesday, March 4th. The shares were sold at an average price of $516.67, for a total value of $5,166,700.00. Following the completion of the sale, the chief executive officer now directly owns 115,174 shares of the company's stock, valued at $59,506,950.58. This represents a 7.99% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Gianluca Pettiti sold 300 shares of the stock in a transaction that occurred on Monday, April 28th. The stock was sold at an average price of $429.93, for a total transaction of $128,979.00. Following the completion of the sale, the executive vice president now directly owns 23,167 shares of the company's stock, valued at $9,960,188.31. This trade represents a 1.28% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 14,075 shares of company stock worth $7,305,942 over the last ninety days. 0.33% of the stock is currently owned by company insiders.
Thermo Fisher Scientific Company Profile
(
Free Report)
Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
Featured Articles
Before you consider Thermo Fisher Scientific, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Thermo Fisher Scientific wasn't on the list.
While Thermo Fisher Scientific currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
